Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 7NIH 4INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 159Myeloid 68Lymphoid 24Plasma cell 11Thoracic 7Genitourinary 4Gastrointestinal 4Sarcoma 3Gynecologic 3Classical hematology 3CNS 3Breast 3Tumor-Agnostic 2Head & Neck 2Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 3Anemia, Refractory, with Excess of Blasts 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1GATA2 Deficiency 1

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10Rivaroxaban 9olaparib 5eltrombopag 5apixaban 5Heparin, Low-Molecular-Weight 5pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4emicizumab 4Gemcitabine 4Filgrastim 4Dalteparin 4Cyclophosphamide 4AP 1903 reagent 4romiplostim 3peginesatide 3luspatercept 3hetrombopag 3hematide 3Vancomycin 3ON 01910 3Enoxaparin 3Azacitidine 3ACE-011 3venetoclax 2telapristone acetate 2roxadustat 2iron isomaltoside 1000 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Azacitidine × Classical hematology × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06372717 2026-02-04

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Apollo Therapeutics Ltd

Phase 1 Recruiting
100 enrolled
Classical hematologyOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT01110473 2017-11-20

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

AbbVie

Phase 1 Completed
52 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡